Tag: Year

Trust Stamp Provides a Business Report and Financial Results for the Year Ended December 31, 2023

Trust Stamp

Trust Stamp

Trust Stamp provides a report on its business and financial results for year ended December 31, 2023 and announces that its Form 10-K for year ended December 31, 2023 will be filed with the Securities and Exchange Commission on April 1, 2024

Atlanta, GA, March 27, 2024 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI), the Privacy-First Identity Company ™ providing AI-powered trust and identity services used globally across multiple sectors, announced financial results and provided a business update for year ended December 31, 2023.

Trust Stamp Chief Executive Officer, Gareth N. Genner commented, “I am pleased to report our progress for the year ended December 31, 2023.

The relationship with our long-term customers remains very strong and we anticipate continued long-term growth in the revenue derived from those relationships.

In respect of new customers, a significant number of additional financial institutions integrated with our Orchestration Layer both via our channel partnership and directly, bringing the total number of integrated institutions as at the date of our 10-K filing to 43 financial institutions representing a fivefold increase in our financial institution customer base since the start of 2023. We had forecast nominal revenue from those new customers in 2023 as the financial institutions integrate and roll-out both internally and eventually with their end-users, and we continue to anticipate recurring revenue from those integrations starting in 2024. We believe that the lengthy lead period from first engagement to significant revenue for integrating financial institutions will be rewarded by the consistency and longevity of the resulting revenue streams.

Our 2023 focus on US-based banks via our channel partnership with FIS has now been augmented by our participation in the acclaimed ThinkTech program operated by The Independent Community Bankers of America. This engagement has already resulted in tailoring some of our product

Read More ...

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results

Quarterly EsoGuard® revenue increased 33 percent sequentially

Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to Medicare coverage

Conference call and webcast to be held tomorrow, March 26th at 8:30 AM ET

NEW YORK, March 25, 2024 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( “PAVmed”), today provided a business update for the Company and presented financial results for the year ended December 31, 2023.

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)

Conference Call and Webcast

The webcast will take place on March 26, 2024, at 8:30 AM, and be accessible in the investor relations section of the Company’s website at luciddx.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid Diagnostics Business Update” to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at luciddx.com.

Business Update Highlights

“We are very pleased with the excellent progress Lucid has made on multiple fronts in the fourth quarter and recent weeks,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “We saw solid revenue growth on stable test volume and our revenue cycle management processes are yielding improving allowances and stable pricing. Our #CYFT program targeting firefighters and other groups is thriving and we have a

Read More ...

I-Mab Reports Full Year 2023 Financial Results and Business Update

  • Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024
  • Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inhibitors for patients with newly diagnosed NSCLC in 1H 2024
  • First patient dosed in an ongoing, triplet combination, dose escalation study of givastomig (CLDN18.2×4-1BB bispecific antibody) in 1Q 2024
  • RMB2.3 billion (US$321.8 million) in cash and cash equivalents, and short-term investments as of December 31, 2023

ROCKVILLE, Md., March 14, 2024 /PRNewswire/ — I-Mab (the “Company”) (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.

“2023 was a transitional year for I-Mab and we were pleased to report encouraging clinical results in our two lead global assets in oncology, uliledlimab and givastomig. As we prepare for the closing of the strategic divestiture, we look forward to providing investors with a road map to value creation and believe that our differentiated clinical assets, uliledlimab, givastomig, and ragistomig will achieve critical milestones and trial initiations this year,” said Raj Kannan, Director and Chief Executive Officer of I-Mab.

Pipeline Overview and Upcoming Milestones:

Uliledlimab: Phase 2, with a focus on non-small cell lung cancer (NSCLC)

Uliledlimab is designed to target CD73 and promote stronger activation of the patient’s immune system against cancer cells. Uliledlimab is potentially differentiated from other products in development due to its non-competitive binding with adenosine monophosphate and the potential for complete inhibition of CD73’s immune dampening function. Encouraging results from a Phase 2 study of uliledlimab in

Read More ...

Comcast Business Named ‘Best Internet Service Provider’ for 13th Consecutive Year by New Hampshire Business Review

MANCHESTER, N.H., March 15, 2024–(BUSINESS WIRE)–Comcast Business announced today, that for the 13th consecutive year, it has been selected as the number one Internet service provider by New Hampshire Business Review readers. The company was recognized for its unique and forward-thinking service offerings, and dedication to meeting the evolving needs of the many businesses throughout the Granite State.

The recognition is part of the New Hampshire Business Review’s annual Best of Business (BOB) Awards program which identifies, recognizes and honors the top companies across the state. More than 3,000 votes were cast using anonymous online surveys from more than 500 businesses across New Hampshire to assess satisfaction to select this year’s award recipients. The publication unveiled the winners, spanning a range of 70+ business-to-business categories, during an annual celebration on Thursday, March 14 at the Grappone Conference Center in Concord.

“Comcast Business is honored to receive this Best of Business recognition. We’re truly thankful for our loyal customers and local business community, they deserve all the credit for our selection as the number one Internet provider in New Hampshire,” said Paul Savas, vice president of Comcast Business for Comcast’s New England region, which includes New Hampshire. “Receiving this award for the 13th consecutive year showcases the dedication that Comcast Business has to further expanding our innovative services and reach across this great state.”

New Hampshire Business Review is the state’s only business newspaper, reaching more than 50,000 subscribers every other week. It is part of Yankee Publishing Inc., a publishing company that also includes New Hampshire Magazine, Yankee Magazine and 603 Diversity, among others. To view a full list of the 2024 winning businesses, visit www.bobawardsnh.com.

About Comcast Business

Comcast Business offers a broad suite of technology solutions to keep businesses

Read More ...

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.

To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13744458, or click on this Link and request a return call. The audio webcast can be accessed on the “Events and Presentations” page under the “Connect” tab of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need.

  • Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

  • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not U.S. Food and Drug Administration (FDA)-approved.

  • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and

Read More ...

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Prime Medicine, Inc.

Prime Medicine, Inc.

Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 —

— Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease programs in 2024 —

— Advancing hotspot and PASSIGE™ Prime Editors for CF following entry into therapeutic development agreement with Cystic Fibrosis Foundation —

— Completed upsized $161 million public offering —

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.

“In 2024, we anticipate undergoing a significant transformation, maturing into a clinical-stage company and bringing the first-ever Prime Editing-based therapeutic candidate to patients. We look forward to filing our first IND or CTA in the months ahead, and to commencing our Phase 1 clinical trial in CGD, a serious, life-threatening disease that we believe is uniquely suited for treatment with a Prime Editing-based approach,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. “In parallel, we continue to progress our broader pipeline, where we are advancing programs across our core areas of focus: hematology and immunology, liver, lung, ocular and neuromuscular disease. This year, we expect to advance our first liver and ocular disease programs into IND-enabling studies, while continuing to explore business development opportunities that can accelerate our existing work, enable us to pursue additional programs, and provide access to innovation that can further advance Prime Editing. Over time, we believe the modularity of the Prime Editing platform will allow us to quickly build on our current efforts, unlocking opportunities across a

Read More ...

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

  • Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0 million

  • The company expects cash guidance for the full year 2024 net cash used in operating and investing activities to be $208 to $225 million and expects to end the year with approximately $405 million in cash (midpoint)

  • Advanced potential best-in-class Alzheimer’s disease portfolio in 2023: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; reported Phase 1 data for BMS-986446 (formerly PRX005), an anti-tau antibody, data supports moving into a Phase 2 clinical trial by partner Bristol Myers Squibb

  • Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis; published Phase 3 VITAL clinical trial data in Blood, the peer-reviewed journal of ASH

  • Received $55 million milestone payment from Bristol Myers Squibb in July 2023 for exclusive worldwide license to BMS-986446 (formerly PRX005)

DUBLIN, February 15, 2024–(BUSINESS WIRE)–Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2023. In addition, the Company provided 2024 financial guidance and business highlights.

“2023 was a year of strong progress for Prothena as we advanced our protein dysregulation portfolio and moved closer to becoming a fully integrated commercial company. The next 12 to 18 months have the potential to transform Prothena with multiple upcoming clinical readouts across our robust portfolio,” said Gene Kinney, Ph.D.,

Read More ...

Business insolvencies shot up by more than 41% last year, as pandemic debts mount

Business insolvencies jumped by more than 41 per cent in 2023, according to data released Friday by Canada’s top financial regulator.

The report from the Office of the Superintendent of Bankruptcy showed that the total number of insolvencies — meaning those filed by both businesses and consumers — was up by 23.6 per cent last year.

The high insolvency rates for businesses are “telling a story that we’ve been a little concerned about, and that is essentially that we’re seeing a very tough economic climate for a lot of businesses” amid low economic activity, said Pedro Antunes, chief economist at the Conference Board of Canada.

“Profits have plummeted and we’ve seen the stresses of CEBA loan repayments due, and perhaps other stresses coming into play,” he said, adding there might be more job losses in the coming months.

He said that if things start to unravel, there’s still room for the Bank of Canada to lower interest rates, which would help businesses repay their loans and reduce the need for job cuts.

“But we’re at that crux. We’re at that moment where everybody’s kind of holding their breath to see what’s going to come of this,” he noted.

A man with a neutral expression and wearing a blue suit jacket stands next to a staircase.
Richard Goldhar, a licensed insolvency trustee, says phones are ringing off the hook at his Toronto-based bankruptcy firm. (CBC)

The Canadian Association of Insolvency and Restructuring Professionals (CAIRP) said in a statement that Friday’s numbers marked the sharpest increase in business insolvencies in 36 years of records. Analysts were expecting businesses to be hit hard in 2023, with many having fallen behind on their pandemic loan repayments.

Finance Minister Chrystia Freeland said on Jan. 23 that a quarter of small businesses that took out a Canadian emergency business account (CEBA) loan had missed the repayment-with-partial-forgiveness deadline of Jan. 18.

“Many businesses are

Read More ...

Rewind 2023: A transformative year for Media, Marketing, Advertising – Irvinder Ray

It’s time to review the most significant industry developments as the year 2023 draws to a close. Adgully is reviewing the year 2023 for M&E, Advertising, Digital, Marketing, PR, and communications, along with leading names in the industry as part of its annual Rewind series.

Recapping the year 2023, Irvinder Ray, Partner, Deloitte India, recalled how the year 2023 was a transformative year for the Media, Marketing, and Advertising industry in India, demonstrating innovation and resilience in the face of economic challenges, quickly adapting to changes, with noteworthy developments in artificial intelligence, programmatic technology, and data analytics. Moreover, there was a considerable shift towards content that was more interactive and personalised.

Insights and analytics driven by AI have helped advertisers to comprehend consumer behaviour at a deeper level, thereby leading to targeted advertising and improvement in campaign effectiveness with the optimisation of ad spending, says Ray. There was a significant shift towards customer-centric contentas well as the increase in influencer marketing, usage of data technology for better quality ads, and more personalised, eco-friendly messaging and content. Leveraging AR and VR in ads is another highlight of 2023. The shift from traditional to digital media was all the way more evident.

Media, Marketing, and Advertising ecosystem in 2023

The year 2023 was a transformative one for the Media, Marketing, and Advertising ecosystem in India. Despite challenges posed by external economic factors, the industry demonstrated resilience and innovation, responding with agility to shifting market trends. Significant strides were made in digital advertising, particularly in areas such as programmatic technology, artificial intelligence, and data analytics. The growth trajectory of the OTT sector denoted the continued rise of digital content consumption amongst Indian audiences.

The industry adapted to changing consumer behaviours, with a noticeable shift towards personalized and interactive content. AI-driven analytics and insights

Read More ...

Programmatic Marketing or Advertising Market Will Touch New Level in Upcoming Year | 124 Report Pages

Latest Programmatic Marketing or Advertising Market Growth Analysis 2023

Programmatic Marketing or Advertising Market 2023 with 124 Pages Report and enhance with extents shares into sub-counties are covered in this market. Programmatic Marketing or Advertising Market conditions can be influenced by a wide range of factors, including economic policies, geopolitical events, and technological developments.

Major Key Players of the Market:



Adobe Media Optimizer





The Trade Desk

Marin Software


Quantcast Advertise

Facebook Business

Yahoo Gemini


Get a Sample PDF of report @ https://www.360marketupdates.com/enquiry/request-sample/20503163

Browse Market Size, charts, tables and figures extent in-depth TOC with 124 Report Pages on Programmatic Marketing or Advertising Market by Application (, Marketing and Advertising, Health, Wellness and Fitness, Construction, Others, ), by Type (, Programmatic RTB, Programmatic Direct, , ) Business Outlook, Top Companies, Key Regions, Product Demand, Market Size and Growth.

Programmatic Marketing or Advertising market focuses on analyzing the current competitive situation in the Programmatic Marketing or Advertising market and provides basic information, market data, product introductions, etc. of leading companies in the industry. At the same time, includes the highlighted analysis–Strategies for Company to Deal with the Impact of COVID-19, It may also be helpful to consult with a financial who can provide direction based on your specific financial situation and goals.


COVID-19 has had a significant impact on many industries. The pandemic has disrupted global supply chains, leading to shortages of certain goods and materials. It has also resulted in decreased demand for some products and services, as people have been staying home more and spending less money on non-essential items. Many businesses have had to close temporarily or permanently due to lockdowns and social distancing measures. Some

Read More ...